Other
Complicated Intra-Abdominal Infections
0
Pipeline Programs↗
1
Active Trials↗
7
Companies Involved↗
Complicated Intra-abdominal Infections is an early-stage landscape with 0 programs across 7 companies. The most active players are Pfizer, Tetraphase Pharmaceuticals, Inc, Merck & Co..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
18
clinical trials
Completed15 · 83%
Terminated2 · 11%
Recruiting1 · 6%
Clinical Trials
Trial Activity
18 trials
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
Completed·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00229060·483 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00229060·483 enrolledDoripenem in the Treatment of Complicated Intra-Abdominal Infections
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210938·478 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210938·478 enrolledPage 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)